Milestone/deliverable #1
Other Transaction IDV Awarded Last action
- Contract number
- W911SR2290005
- Awardee
-
Gigagen Inc. UEI HF7MJJDVQQX5
- Awarding agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Task orders
- 0
Award facts
- Last date to order
- Not on record
- IDV ceiling
- $2,182,837.00
- Contracting staff
- Funding agency
- Joint PEO Chemical and Biological Defense Acquisition Support Center, Department of Defense
- NAICS code
- Not on record
- Set-aside
- No set-aside
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
Award details come from SAM.gov/FPDS.
About this IDV
Gigagen Inc. was awarded a multiple-award Other Transaction Indefinite Delivery Vehicle on July 14, 2022, by the Joint Program Executive Office (PEO) Chemical and Biological Defense, a defense-focused component within the Department of Defense. The contract carries a ceiling value of $2.2 million and contains no set-aside provisions. The primary deliverable under this vehicle involves the development and production of a recombinant polyclonal hyperimmune medical countermeasure specifically targeting botulism toxin, which has been designated as a Department of Defense priority pathogen. This recombinant polyclonal approach represents an advanced immunological therapeutic strategy designed to provide protection against biological threats relevant to military and homeland defense operations.
The Other Transaction authority granted under this IDV provides flexibility for the government to expand the partnership beyond the initial botulism toxin focus through various options, permitting the potential inclusion of other Department of Defense priority pathogens as identified needs emerge. This contract structure aligns with the Defense Department's strategic objective to develop medical countermeasures against chemical and biological warfare agents and naturally occurring biological threats. The use of an Other Transaction vehicle rather than traditional contracting mechanisms indicates the government's intent to foster innovation and flexibility in the development of these critical medical defense capabilities, with performance to be accomplished through task orders issued under the IDV authority.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | $324,788 | |
| Supplemental Agreement for work within scope | $327,873 | |
| Funding Only Action | $689,317 | |
| Funding Only Action | $225,539 | |
| Supplemental Agreement for work within scope | $515,320 | |
| Other Administrative Action | $0 | |
| Original award | $100,000 |
Quick answers
Who was awarded contract W911SR2290005?
W911SR2290005 was awarded to Gigagen Inc. by ACC Aberdeen Proving Ground (Army Contracting Command) on July 14, 2022.
How much is contract W911SR2290005 worth?
W911SR2290005's own ceiling is $2,182,837.
Which agency awarded contract W911SR2290005?
ACC Aberdeen Proving Ground (Army Contracting Command) awarded W911SR2290005, with funding from Joint PEO Chemical and Biological Defense (Acquisition Support Center).
Was contract W911SR2290005 competed?
The extent of competition for W911SR2290005 was competed.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV